微生物组调节治疗实体肿瘤
本文综述了肠道微生物组与免疫系统相互作用在肿瘤治疗中的研究进展。临床前研究识别出与免疫检查点抑制剂(ICI)疗效相关的特定菌种,并在黑色素瘤、肾细胞癌(RCC)和非小细胞肺癌(NSCLC)中开展了临床研究。尽管观察到多种微生物调节策略的积极信号,但该领域缺乏大型确定性随机试验,这是任何策略成为标准治疗的前提。
要点
- Ruminococcaceae、Akkermansia和Bifidobacterium的粪便细菌丰度与有利的临床结局相关。
- ICI启动前或期间使用抗生素破坏肠道微生物组与更高的原发耐药率和更短生存期相关。
- 已开发TOPOSCORE等生物标志物以更好地预测ICI获益并估计生态失调和治疗反应。
核心结论
- 尽管微生物组调节已观察到若干有力信号,但该领域缺乏大型确定性随机试验,这是任何重点策略成为标准治疗的前提。
研究设计与样本
- 本文为综述,检索范围未在原文中明确报告。
主要发现
- Ruminococcaceae、Akkermansia和Bifidobacterium的粪便细菌丰度与有利的临床结局相关。
- ICI启动前或期间使用抗生素破坏肠道微生物组与更高的原发耐药率和更短生存期相关。
- 已开发TOPOSCORE等生物标志物以更好地预测ICI获益并估计生态失调和治疗反应。
- 高膳食纤维摄入可能与改善的结局相关。
- 某些益生菌在早期试验中纳入基于ICI的方案时似乎增强临床活性。
关键数值与推荐
- Ruminococcaceae、Akkermansia和Bifidobacterium的粪便细菌丰度与有利的临床结局相关。
- ICI启动前或期间使用抗生素与更高的原发耐药率和更短生存期相关。
- TOPOSCORE等生物标志物已开发用于更好地预测ICI获益并估计生态失调和治疗反应。
- 高膳食纤维摄入可能与改善的结局相关。
- 某些益生菌在早期试验中纳入基于ICI的方案时似乎增强临床活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 该领域缺乏大型确定性随机试验,这是任何重点策略成为标准治疗的前提。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The interplay between the human gut microbiome and the immune system has sparked growing interest in microbiome modulation as a therapeutic strategy in oncology. Preclinical studies have identified specific bacterial species linked to improved responses to immune checkpoint inhibitors (ICIs), leading to clinical investigations in melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). The stool bacterial abundance of Ruminococcaceae, Akkermansia, and Bifidobacterium correlates with favorable clinical outcomes, whereas the disruption of the gut microbiome through antibiotics before or during ICI initiation is associated with higher rates of primary resistance and shorter survival. Biomarkers such as TOPOSCORE have been developed to better predict ICI benefits and estimate dysbiosis and treatment responses. Several microbiome-modulating strategies have shown potential in patients receiving treatment with ICIs-for instance, high dietary fiber intake may be linked to improved outcomes. As a separate strategy, certain probiotics appear to enhance clinical activity in early trials when incorporated into ICI-based regimens. Finally, fecal microbiota transplantation has shown safety and efficacy in ICI-refractory melanoma and yielded encouraging results in treatment-naïve patients with melanoma, NSCLC, and RCC. Although several compelling signals have been observed to date with microbiome manipulation, the field is lacking large, definitive randomized trials-these are indeed a prerequisite for any of the highlighted strategies to become a standard of care.
引用
- Barragan-Carrillo R, Zengin ZB, Pal SK, et al. Microbiome Modulation for the Treatment of Solid Neoplasms. J Clin Oncol. 2025. PMID: 40644647. doi:10.1200/JCO-25-00374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。